Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: Bayer
• Treatments: Riociguat

Criteria

Inclusion Criteria:

• Adult patients who underwent PTE for Chronic thromboembolic pulmonary hypertension (CTEPH) at least six months prior to screening and report ongoing subjective exercise limitation,

• able to give consent

• able to perform a exercise protocol

Exclusion Criteria:

• Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for CTEPH

• ongoing PAH-specific vasodilator therapy

• known contraindication to riociguat

• a physical limitation to completing an exercise protocol